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Background: At our hospital the current model of care for children with moderate–severe CF is focused on intensive inpatient intervention, regular
outpatient clinic review and specialist outreach care as required. An alternative model providing more regular physiotherapy and dietetic outreach
support, in addition to these specialist services, may be more effective.
Methods: 16 children (4 male; 12 female; mean age 10.9±2.93; range 4–15 years) who required N40 days of IV antibiotics in the 12-months pre-
intervention were enrolled. Physiotherapy included weekly-supervised exercise sessions, alongside regular review of home physiotherapy
regimens. Dietetic management included 1–2 monthly monitoring of growth, appetite, intake and absorption, and nutrition education sessions.
Results: There was a 23% reduction in inpatient IV antibiotic requirement and 20% reduction in home IV antibiotic requirement during the
intervention year. Cost–beneﬁt analyses showed savings of £113,570. VO2Peak increased by 4.9 ml·kg·min
−1 (95%CI 1.01 to 8.71; p=0.02), and
10 m-MSWT distance and increment achieved increased by 229 m (95%CI 109 to 350; pb0.001) and 2 levels (95%CI 1 to 3; pb0.002)
respectively. No signiﬁcant differences in physiological and patient reported outcomes were demonstrated, although there was a possible trend
towards improvement in outcomes when compared to the pre-intervention year.
Conclusion: This pilot programme demonstrated a reduction in IV and admission requirements with a cost beneﬁt in a small group of children with
moderate–severe CF. A fully powered clinical trial is now warranted.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Exercise; Physiotherapy; Dietetics; Cystic ﬁbrosis1. Introduction
Regular exercise may help to maintain or increase lung
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http://dx.doi.org/10.1016/j.jcf.2013.01.003techniques in children with cystic fibrosis (CF) [2]. It may also
improve aerobic capacity, muscle strength and lung function [3].
However, it is important to carefully monitor growth and body
composition in children who regularly exercise, as increased
energy demands may impact on body mass index (BMI) that is
strongly correlated with lung function [4].
Two previous observational studies in small groups of children
with moderate–severe CF, one presented in abstract format [5] and
the other recently published [6], reported that a 12-month intensive
outpatient physiotherapy and exercise programme significantlyby Elsevier B.V. All rights reserved.
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also increased exercise capacity.
The 12-month pilot Frequent Flyer Programme (FFP) was
undertaken as a quality improvement initiative within the CF Unit
of Great Ormond Street Hospital for Children (GOSH), in addition
to the specialist services already provided. The purpose was to try
and replicate these positive results and to determine feasibility for
a larger controlled trial. The investigators hypothesised that re-
duced inpatient admissions would benefit the children and be
economically advantageous to the hospital. Additionally, in-
creased exercise capacity may help to maintain or increase lung
function. A dietetic component was included to monitor for
changes in growth and energy requirements as a result of increased
exercise.
This was a pragmatic clinical intervention, targeted at a
specific population, so a pre-intervention power calculation was
not performed, and there was no blinding of clinicians involved
with the programme. Weekly outreach physiotherapy and more
regular nutrition support were provided to a small group of
children who required multiple courses of IV treatment in the
previous year. The primary outcome was the total number of IV
days required in the 12-month intervention period, compared to
12-months pre-intervention. A cost-analysis was also undertaken.
Secondary outcomes included exercise capacity, lung function,
growth and body composition, and quality of life (QoL)
assessment.2. Methods
A top-down approach was applied, such that children from the
GOSH CF cohort (n=178) with the most IV requirements in the
pre-intervention year were enrolled first on the programme.
Children were identified by retrospective analysis of the previous
year's admission data. Inclusion criteria were a confirmed
diagnosis of CF, aged 4–15 years, with a baseline FEV1N30%,
and a requirement of N40 days of IV treatment in the 12-months
pre-intervention. No microbiological exclusion criteria were set.
The Chairman of the GOSHEthics Committee confirmed that a
full ethics review was not required, nevertheless written informa-
tion was given and verbal consent to participate was obtained from
parents or guardians, and children where appropriate.2.1. Requirement for admissions for routine IV
All participants had pre-scheduled, 3–4 monthly admissions
for routine IV treatment; however, respiratory exacerbations
and bed pressures regularly affected these dates. Requirement
for admission was assessed at an outpatient clinic 2–4 weeks
prior to routine admissions. The attending consultant could
make a clinical decision to bring forward a symptomatic child's
admission, or children maintaining or showing improvement in
clinical status could have their admission delayed. Participants
were typically admitted to GOSH, however, some children
were admitted to their local hospital if part of the GOSH
shared-care network.2.2. Outcome measures
2.2.1. IV and inpatient days
The total number of inpatient IV treatments administered at
GOSH, shared-care hospitals and for IV courses completed at
home, during the 12-months pre-intervention was documented
for each child at baseline. Data for the intervention period were
collated post-intervention.
Physiological and exercise outcome measurements recorded
during times of clinical stability (i.e. not during an exacerbation,
not on steroids, and not during or within 2 weeks of IV treatment)
for 1-year pre-intervention, baseline and post-intervention were
used for analysis.
2.2.2. Cardiopulmonary exercise testing
Cardiopulmonary exercise testing (CPET) was performed at
baseline to identify exercise-induced limitations and provide
parameters for individualised exercise prescription. It was
repeated post-intervention to assess changes in aerobic capacity.
A Godfrey cycle protocol was performed at each session [7], with
continuous respiratory gas analysis (Medgraphics, St. Paul,
Minnesota), electrocardiography and oxygen saturations (SpO2)
monitoring. Participants were encouraged throughout the tests to
make amaximal effort. The test was consideredmaximalwhen the
participant achieved one of the following: 1) heart rate N90%
age-predicted maximum; 2) respiratory exchange ratio (RER)
≥1.05; or 3) a peak minute ventilation (VE) close to predicted
target [8,9]. Children aged b6 years, or those that did not meet the
minimum 120 cm height requirement at baseline to sit safely on
the ergometer bike, were excluded from CPET. Additionally,
those infected with methicillin-resistant Staphylococcus aureus
(MRSA) or Burkholderia cepacia were excluded due to infection
control risks.
2.2.3. 10m modified shuttle walk test
The 10m modified shuttle walk test (10m-MSWT) was
performed at baseline and post-intervention to assess functional
exercise capacity [10,11].
2.2.4. Lung function
Spirometry (Erich Jaeger AG, Wurzburg, Germany), height
(Holtain Ltd, Dyfed, UK) and weight (Seca, Birmingham, UK)
were measured at baseline, regularly during the 12-month
intervention period, and post-intervention. Spirometry was
performed according to GOSH laboratory standards, which are
based on ERS/ATS guidelines [12].
2.2.5. Growth and body composition
Body composition measurements were performed at baseline
and post-intervention. Left sided, mid-upper arm circumference
(MUAC) [13] and the mean of three measurements of biceps,
triceps and subscapular skinfold thickness (SFT) (Holtain Ltd,
Dyfed, UK) were used to estimate fat mass [14]. Using a pre-
viously described method [15], deuterium dilution techniques
were used as a proxy for calculating leanmass, and were analysed
by Iso-Analytic Ltd (Sandbach, UK).
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The Cystic Fibrosis Questionnaire UK version (CFQ) [16]
was completed at baseline and post-intervention to evaluate
changes in QoL. Children aged≥14 years used the self-assessed
CFQ-14+ version, whilst those aged 6–13 used age appropriate
clinician assisted versions. Children and parents completed a
satisfaction questionnaire post-intervention.
2.3. Intervention
2.3.1. Physiotherapy
The physiotherapist used FEV1, CPET and 10m-MSWT
results to prescribe an age appropriate, individualised exercise
programme. Exercise training compromised of high intensity
interval training using cardiovascular training equipment (e.g.
treadmill, bike, and cross-trainer) interspersed with periods of
recovery. This allowed for recovery from breathlessness, and
huffing and coughing was performed to facilitate airway
clearance. Strength, core-conditioning and stretching compo-
nents were also included. Children with a baseline FEV1N70%
exercised for 45–60 min, of which 20–30 min was at 70–85% of
maximum heart rate (HRMax), whilst children with a baseline
FEV1=39–69% exercised for 30–45 min for 15–25 min at 60–
80% HRMax. HRMax was monitored by portable Nonin 2500
SpO2/HR monitors (Nonin Medical Inc., Plymouth, USA). In
addition, children were also encouraged to exercise independent-
ly, and actively participate in school PE lessons and sport for an
additional 2 hours per week. Free membership to a local fitness
facility was negotiated for each of the children, at which the
physiotherapist supervised weekly training sessions.
Home physiotherapy regimens were reviewed monthly to
reinforce optimal airway clearance and mucolytic inhalation
therapy. When parents reported an exacerbation of respiratory
symptoms, the physiotherapist would assess the child at home or
clinic, escalate home physiotherapy treatment and collect a sputum
sample. The physiotherapist would also coordinate with the
multidisciplinary team (MDT) when a course of oral antibiotics
was necessitated.
2.3.2. Dietetics
Increased input from the dietitian included a minimum of 1–2
monthly monitoring of weight. Assessment of appetite, intake,
and absorption was through verbal consultation telephonically, at
clinics, during inpatient admissions and occasional home visits.
Focus was on the child's response to exercise with additional
calorie supplementation prescribed when needed. The dietitian
reviewed oral supplements, enteral feeds, vitamins, enzyme ad-
ministration and dosage. Educational resources were developed
and individualised nutrition sessions were delivered to the child
about pancreatic enzyme therapy, energy requirements, and vi-
tamin and mineral needs.
2.4. Statistical analysis
Data were entered into a Microsoft Excel database and
statistical analyses were undertaken using IBM®SPSS® Statistics
21 (Chicago, IL, USA). Lung function [17], weight, height, BMI[18,19] and body composition [20], results were converted to
z-scores. A repeated measures test was used to compare pre-
intervention, baseline and post-intervention data. Paired t-tests
were used to compare data at baseline and post-intervention only.
Data were expressed as mean±standard deviation (SD), 95%
confidence intervals (CI), and an alpha level of 0.05 was
established for statistical significance.
2.5. Healthcare cost analysis
Cost analyses were completed post-intervention. Two
methods were used to evaluate the cost implications of the
programme. First, a comprehensive internal cost analysis
determined that the cost per day for GOSH inpatient admissions
for this cohort were approximately £1210 per day. Internal cost
analysis was calculated on audited MDT staffing costs; cost of
blood, radiological and pathology tests; drug expenses; device
and clinical support expenses; and theatre and ward expenses.
Home IV costs were calculated at £168 per day based on costs
provided by the supplier, Willow Healthcare Services UK.
Second, the published generic National Health Service (NHS)
unit reference costs for a paediatric hospital bed are approxi-
mately £658 per day [21]. Shared-care inpatient costs were
determined using NHS unit costs, as full internal costing was
impractical.
Setup-cost for the programme was £100,000 to include a
full-time physiotherapist, part-time dietitian, lease of vehicle,
road-tax and diesel costs. Children in this programme availed of
a free gym membership. However, other centres implementing
this type of intervention may have to consider the cost of gym
memberships in setup-costs. Personal communication with these
facilities determined cost per membership for a child ranged
between £15 (local council leisure centre) to £52 (nationwide
health and wellbeing centre) per month. Cost–benefit analysis
included these potential costs.
3. Results
3.1. Participants
Twenty children were eligible to participate. Two children
received lung transplantation before baseline data was collected
and were therefore not enrolled. One child did not wish to
participate and one child was excluded due to pre-existing
social concerns.
Sixteen children (4 male) aged 4–15 years (10.9±2.93) started
the programme. All, but two, completed the programme; one child
relocated and one diedmidway through the programme. Both were
excluded from final analysis. Nine children were homozygous for
the ΔF508 genotype and all, except 1, had pancreatic insufficien-
cy. This child was excluded from growth and body composition
analysis, as dietetic requirements and management were very
different to the pancreatic insufficient children. One child received
maxillofacial surgery in the last month of the programme and
therefore did not complete CPET or body composition measure-
ment post-intervention. Descriptive baseline demographics are
presented in Table 1.
Table 2
IV antibiotic day requirement for 12-months pre-intervention and post-intervention.
Venue
(no. of patients)
Total
pre-intervention
Total
post-intervention
Total diff.
(mean diff)
GOSH IV days (16) 619 (39±27) 478 (30±37) −141 (−8.8)
Home IV days (7) 304 (43±18) 243 (35±15) −61 (−8.7)
Shared care IV days (8) 249 (31±27) 189 (24±20) −60 (−7.5)
Total (16) 1172 (73±25) 910 (57±41) −262 (−16.4)
Data presented as total (mean±standard deviation).
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There was a 21% reduction in the requirement for GOSH
inpatient IV treatment, from 619 days in the pre-intervention
year to 478 in the intervention year; a 24% decrease in
shared-care inpatient IV requirement from 249 to 189 days; and
a 20% reduction in home IV treatment from 304 to 243 days.
The overall 22% reduction in IV requirement represented a
substantial reduction when compared to pre-intervention data
(Table 2).3.3. Healthcare costs
Full internal cost analyses (Table 3) determined there was an
estimated saving of £170,610 in GOSH inpatient costs; £39,480
in shared-care hospital bed costs; and £10,248 in home IV
costs. Average cost per patient during the pre-intervention year
was £60,244 compared to £46,472 in the intervention year
demonstrating a mean cost saving per patient of £13,772. An
alternative cost analysis, employing generic NHS bed costs
only, is detailed in the online supplement.
After factoring in the £100,000 set up costs for the programme,
plus estimated annual gym memberships costs of £6768, the
average cost per patient during the intervention year was £53,146
suggesting an overall cost saving of £7098 per patient or
£113,570 overall.3.4. Cardiopulmonary exercise testing
Thirteen children met the minimum requirements to perform
CPET. Of these, one child refused to participate due to intolerance
of the facemask, and one was not able to repeat the test as she had
maxillofacial surgery. Post-intervention, paired t-tests showed
a statistically and clinically significant increase in VO2Peak of
4.9 ml·kg·min−1 (CI 1.0 to 8.7; p=0.02) and VO2Peak%pred by
14% (CI 1.9 to 25.8; p=0.03*) (Table 4). All children maintained
SpO2N95% during testing and no arrhythmias were detected.Table 1
Baseline demographics for group.
Variable Number
Male/female 4/12 (n=16)
Mean age±SD [range] 10.9±2.93 [4 to 14]
Genotype ΔF508/ΔF508=9
ΔF508/other=5
Other mutations=2
Pancreatic insufficiency 15
CF related diabetes 1
Impaired glucose tolerance 1
Indeterminate glycaemia 1
Microbiology
Chronic Pseudomonas aeruginosa 10 (63%)
Chronic Staphylococcus aureus 1 (1%)
Chronic methicillin-resistant Staphylococcus aureus 1 (1%)
History of allergic bronchopulmonary aspergillosis 5 (31%)
History of nontuberculous mycobacteria 3 (19%)3.5. 10 m modified shuttle walk test
Thirteen children completed 10m-MSWT; one child aged 5
was not tested. Paired t-tests showed a statistically and clinically
significant increase in distance walked or run and number of
increments achieved, by 229m (CI 108.8 to 349.7; p=0.001) and
2 levels (CI 0.8 to 2.6; p=0.002) respectively (Table 4).
3.6. Lung function
Repeated measure tests showed no statistically significant
differences in FEV1 z-scores over time. Mean FEV1%pred for
the group declined significantly by N9% (CI −17.1 to −1.1; p=
0.02) in the pre-intervention year. Although non-statistically
significant, the difference in rate of change between baseline to
post-intervention and pre-intervention to baseline, FEV1%pred
had improved by almost 9% (CI −3.3 to 23.0; p=0.13). This
may suggest a possible trend towards slowing the rate of
decline. When converted to z-scores the results suggest a
similar trend. Physiological data are presented in Table 5.
3.7. Growth and body composition
At baseline, 3 children were classified as malnourished
(BMIb15th percentile) [22]. Two children (both female) had a
gastrostomy in situ and 10 children were receiving oral calorie
supplements. Repeated measure tests showed no statistically
significant differences in growth parameters. Changes in BMI
and lean mass z-scores are graphically presented in the online
supplement.
Ten children maintained a BMI z-score within 0.5 of their
baseline measurement during the intervention. One child who was
categorised as malnourished at baseline increased their BMI
z-score by 0.5 post-intervention. However, 2 children with good
baseline nutritional status showed a decline N0.5 in BMI z-score
post-intervention. Similar trends were noted for weight. Post-
intervention 7 children were taking oral supplements; 4 were
taking increased amounts including one child who was referred
for a gastrostomy, and 2 used occasional oral supplements.
Twelve children completed deuterium dilution testing, MUAC
and SFT measurements. Paired t-tests showed no statistically
significant changes in lean mass and MUAC z-scores. There was
a statistically significant increase of 0.4 (CI 0.2 to 0.7; p=0.001)
in the aggregated group SFT z-scores. Five children (2 pubertal
boys, 1 pubertal girl and 2 pre-pubertal girls) increased their lean
mass z-scores (range 0.01 to 0.3); however, as a group, there was
Table 3
Cost analysis for 12-months pre-intervention and post-intervention.
Cost; number of patients Total cost pre-intervention
(mean±SD)
Total cost post-intervention
(mean±SD)
Total cost difference
(mean cost diff)
Daily GOSH a admission cost approx. £1210 a, n=16 £748,990 (46,812±33,054) £578,380 (36,149±44,319) −£170,610 (−10663)
Daily cost of home IV-antibiotic treatment approx. £168; n=7 £51,072 (7,296±3,005) £40,824 (5,832±2,542) −£10,248 (−1464)
Daily cost of shared care hospital bed approx. £658; n=8 £163,842 (20,480±17,675) £124,362 (15,545±13,430) −£39,480 (−4935)
Total cost of hospital admission and home IV treatment; n=16 £963,904 (60,244±29,556) £743,566 (46,472±48,696) −£220,338 (−13,772)
Total cost plus setup costs b and gym membership cost c; n=16 £963,904 (60,244±29,556) £850,334 (53,146±48,641) −£113,570 (−7098)
Data presented as Total (mean±standard deviation).
a GOSH internal cost analysis was calculated on audited MDT stafﬁng costs; cost of blood, radiological and pathology tests; drug expenses; device and clinical
support expenses; and theatre and ward expenses.
b Total setup cost=£100,000.
c Estimated annual gym membership costs=£6768 [Range £15–£52].
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z-scores.
3.8. Patient reported outcomes
There was a non-statistically significant increase of 1.3% in
total CFQ scores from 71% to 72.3% for the group. Graphic
representation of CFQ scores and further discussion are presented
in the online supplement. The results of the end of programme
evaluation questionnaires showed that patients (76%) and parents
(79%) highly rated both the physiotherapy and dietetic compo-
nents of the programme. All said they would recommend this
type of programme for other children with CF.
4. Discussion
The 12-month FFP demonstrated that intensive weekly
outreach physiotherapy and exercise, and more frequent dietetic
support can reduce requirements for IV treatment in a small
group of children with moderate–severe CF. Cost savings were
realised and exercise capacity was significantly increased.Table 4
Exercise test data at baseline and post-intervention.
Outcome Baseline Po
CPET (n=11)
VO2Peak%pred in % 69.6±18.5 8
VO2Peak at anaerobic threshold (ml.kg.min
−1) 20.0±7.2 2
VO2Peak (ml.kg.min
−1) 28.8±8.8 3
HRMax (BPM) 160.0±20.7 16
RER 1.06±0.12 1
VE/VCO2 33.6±6.8 2
VE BTPS (L/min) 37±18
VCO2 (ml/min) 1165±515 1
Pre-exercise SpO2 99.0±3.8 9
SpO2 at VO2Peak 100.3±4.9 9
10 m-MSWT (n=13)
Distance (m) 710±276
Level 9±2
HRMax (BPM) 157.1±19.7 17
Lowest SpO2 94.1±2.8 9
Peak breathlessness (Borg 1–10) 8±1.3
Data presented as mean±standard deviation.
⁎ Statistically signiﬁcant.The FFP was similar in structure to the two previous studies.
Black et al. [5] demonstrated that in 10 children (mean age
13.2) with CF, IV requirement was reduced by 48%. Urquhart
et al. [6] performed a similar intervention in 12 adolescent
subjects (mean age 13.3), and demonstrated a 23% reduction in
IV requirement; improved 10m-MSWT scores; and improved
QoL scores. In addition, cost–benefit, using NHS generic
estimates were calculated. The FFP realised similar decreases in
IV requirement and increases in exercise capacity, with these
increases being independent of lung function. The programme
did not demonstrate changes in physiological or quality of life
scores, although there were possible emerging trends of
slowing the rate of lung function decline.
CPET was used for the first time in this small group to
determine exercise capacity. Results demonstrated a significant
increase of 13% in VO2Peak%pred, suggesting a significant
increase in aerobic exercise capacity. Importantly, participants
who increased their level of cardiopulmonary fitness may have
increased their chances of survival [23]. Every effort was made
to standardise the test procedures, however it should be noted
that CPET was new to these children. Maximal efforts werest-intervention Diff. baseline to post-intervention (95%CI; p-value)
3.5±22.0 13.8 (1.9 to 25.8; 0.03 ⁎)
1.8±8.8 1.8 (−2.9 to 6.5; 0.41)
3.7±9.4 4.9 (1.0 to 8.7; 0.02 ⁎)
6.6±16.3 6.6 (−3.8 to 17.0; 0.19)
.06±0.12 0.00 (−0.04 to 0.05; 0.94)
9.8±11.3 −3.8 (−13.3 to 5.8; 0.40)
49±22 12.1 (−0.35 to 24.5; 0.06)
318±608 153 (−27 to 332; 0.08)
7.2±2.0 −1.7 (−4.3 to 0.9; 0.17)
6.9±3.6 −3.4 (−6.5 to −0.3; 0.4 ⁎)
940±349 229 (108.8 to 349.7; 0.001 ⁎)
11±3 2 (0.8 to 2.6; 0.002 ⁎)
5.1±11.2 18 (7.1 to 28.9; 0.004 ⁎)
4.8±2.2 0.7 (−1.0 to 2.4; 0.3)
9±1 1 (0.3 to 1.6; p=0.008 ⁎)
Table 5
Physiological data for 12-months pre-intervention, baseline and post-intervention.
Outcome 1-Yr
pre-intervention
Baseline Post-intervention Diff. 1-yr
pre-intervention to
baseline (95%CI;
p-value)
Diff. baseline to
post-intervention
(95%CI; p=value)
Diff. in rate of change
between baseline to
post-intervention and
pre-intervention to
baseline (95%CI; p=value)
Lung function (n=14)
FEV1% predicted 76.6±20.9 67.3±26.0 67.9±21.0 −9.3 (−17.1 to −1.1; 0.02 ⁎) 0.6 (−7.4 to 8.6; 0.88) 8.7 (−3.3 to 23.0; 0.13)
FEV1 (L) 1.3±0.6 1.3±0.5 1.5±0.7 0.0 (−0.3 to 0.3; 0.87) 0.2 (−0.04 to 0.3; 0.12) 0.2 (−0.3 to 0.5; 0.53)
FEV1 z score −2.7±1.6 −3.0±1.6 −3.1±1.6 −0.3 (−1.3 to 0.6; 0.50) −0.1 (−0.6 to 0.4; 0.64) 0.2 (−1.1 to 1.5; 0.76)
FVC% predicted 87.6±16.8 80.6±21.8 82.1±17.1 −7.0 (−14.9 to 0.8; 0.08) 1.5 (−6.5 to 9.5; 0.69) 5.5 (−4.9 to 22.0; 0.19)
FVC (L) 1.7±0.7 1.8±0.6 2.1±0.8 0.1 (−0.3 to 0.4; 0.74) 0.3 (0.1 to 0.4; 0.008 ⁎) 0.2 (−2.3 to 0.6; 0.34)
FVC z-score −1.8±1.7 −2.1±1.5 −2.0±1.43 −0.3 (−1.4 to 0.8; 0.51) 0.1 (−0.4 to 0.5; 0.78) 0.4 (−0.9 to 1.7; 0.53)
Growth (n=13)
BMI z-score −0.2±0.7 −0.3±0.7 −0.4±0.5 −0.1 (−0.5 to 0.2; 0.36) −0.1 (−0.3 to 0.1; 0.35) 0.0 (−0.4 to 0.5; 0.87)
Weight z-score −0.2±0.6 −0.5±0.6 −0.6±0.5 −0.3 (−1.5 to −0.00; 0.05 ⁎) −0.1 (−0.3 to 0.0; 0.10) 0.2 (−0.3 to 0.4; 0.64)
Height z-score −0.2±0.66 −0.4±0.7 −0.5±0.9 −0.2 (−0.3 to −0.04; 0.01 ⁎) −0.1 (−0.2 to 0.08; 0.34) 0.1 (−0.04 to 0.28; 0.14)
Lean mass (n=12)
Deuterium z-score (LMM) – −0.8±1.1 −1.0±1.0 − −0.2 (−0.4 to 0.1; 0.18)
Fat mass (n=12)
Aggregated skin-fold
z-score (FM)
– −0.3±0.6 0.1±0.7 – 0.4 (0.2 to 0.7; 0.001 ⁎)
MUAC – −0.8±0.7 −0.9±0.9 – −0.1 (−0.5 to 0.2; 0.35)
Data presented as mean±standard deviation.
⁎ Statistically signiﬁcant.
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to expect and tried harder in the second test.
The 10m-MSWT was used to confirm the CPET results.
Although significant increases in distance covered and incremental
level achieved were demonstrated, an important potential con-
founder is that age and leg length increases may have contributed
to the increased parameters in the 10m-MSWT when repeated at
yearly intervals. Increased HRMax measurements do suggest that
exercise capacity had increased post-intervention. In both exercise
tests, baseline HRMax was lower than post-intervention, despite
perceived maximal effort; we speculate this may be because
children were less tolerant of breathlessness or less tolerant of
exercising at a high intensity at baseline and may have stopped
before HRMax was achieved.
More frequent dietetic review enabled earlier identification
of nutritional problems and allowed for dietary modifications
to be made to address individual requirements. Children with
poor baseline nutritional status and growth required closer
monitoring. It is well documented [4,24–26] that many
variables may affect growth in children with CF, including
inadequate calorie intake, increased energy expenditure, mal-
absorption, and impaired glucose metabolism. The FFP dem-
onstrated that it could be challenging to maintain steady
growth in some children who exercise more, and some children
reported an added burden of taking more supplements in
response to higher energy requirements.
Notably, in the pre-intervention year, weight and height
z-scores were significantly declining; however, post-intervention,
although results did not reach significance, there was a trend for
the rate of decline to slow. As with the spirometry data, thisprogramme was not powered to assess this comprehensively and
12-months may have been too short a time period to demonstrate
acceleration in growth for those children with poorer nutritional
status.
With an increase in exercise it is important to address
individual energy and nutritional requirements early, with
longitudinal monitoring of growth and nutritional status.
Despite regular strength training, lean mass did not increase.
However as lean mass data was not recorded for the pre-
intervention year, it is not possible to make comparisons with
year on year data. Williams et al. [27] reported that females in
particular have a lower fat mass than the reference population;
this may explain why the predominantly female group in the
FFP did not demonstrate improvements in lean mass.
As with the two previous studies, the FFP had a number of
clear limitations, related to this being a report of an observational
quality improvement initiative, rather than a designed interven-
tion study, and as such is exposed to bias. In assessing the effect
of the intervention, the pre-intervention year was used as the
control sample rather than having separate controls. In addition,
the sample size of the FFPwas not powered to clearly demonstrate
the benefit of this exercise intervention upon lung function.
However, as the FFP has confirmed and extended the findings of
the previous two studies, a fully powered randomised controlled
trial is now warranted, and recruitment for the INSPIRE-CF trial
has commenced.
The FFP demonstrated a reduction in IV requirement with a
cost–benefit, and significant increases in exercise capacity, in
this small cohort of sicker children with moderate–severe CF.
If the positive results realised in this pilot programme were
772 S.J. Ledger et al. / Journal of Cystic Fibrosis 12 (2013) 766–772replicated in other CF units across the UK, the implications for
cost saving, improvement in clinical status and quality of life
are potentially extensive.
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